EWSTEarnings•prnewswire•
Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Sentiment:Positive (65)
Summary
– Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed ARCH and CANYON studies – – Announced encouraging top-line data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 7, 2025 by prnewswire